4.7 Article

Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics

Journal

PHARMACEUTICS
Volume 13, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics13040494

Keywords

COVID-19; tryptophan metabolites; anakinra; molecular pharmaceutics

Funding

  1. Italian Cystic Fibrosis Research Foundation

Ask authors/readers for more resources

The increasing number of clinical studies worldwide is exploring the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to combat the COVID-19 pandemic. However, effective therapies are scarce, necessitating intensified drug discovery and repurposing efforts, along with optimization of the risk/benefit ratio in anti-inflammatory strategies against COVID-19.
An increasing number of clinical studies worldwide are investigating the repurposing of antiviral, immune-modulatory, and anti-inflammatory agents to face the coronavirus disease-19 (COVID-19) pandemic. Nevertheless, few effective therapies exist to prevent or treat COVID-19, which demands increased drug discovery and repurposing efforts. In fact, many currently tested drugs show unknown efficacy and unpredictable drug interactions, such that interventions are needed to guarantee access to effective and safe medicines. Anti-inflammatory therapy has proven to be effective in preventing further injury in COVID-19 patients, but the benefit comes at a cost, as targeting inflammatory pathways can imply an increased risk of infection. Thus, optimization of the risk/benefit ratio is required in the anti-inflammatory strategy against COVID-19, which accounts for drug formulations and delivery towards regionalization and personalization of treatment approaches. In this perspective, we discuss how better knowledge of endogenous immunomodulatory pathways may optimize the clinical use of novel and repurposed drugs against COVID-19 in inpatient, outpatient, and home settings through innovative drug discovery, appropriate drug delivery systems and dedicated molecular pharmaceutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available